These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

230 related items for PubMed ID: 3090092

  • 1. Toward removing uterine fibroids without surgery: subcutaneous infusion of a luteinizing hormone-releasing hormone agonist commencing in the luteal phase.
    Healy DL, Lawson SR, Abbott M, Baird DT, Fraser HM.
    J Clin Endocrinol Metab; 1986 Sep; 63(3):619-25. PubMed ID: 3090092
    [Abstract] [Full Text] [Related]

  • 2. Fourteen-day versus twenty-one-day regimens of intermittent intranasal luteinizing hormone-releasing hormone agonist combined with an oral progestogen as antiovulatory contraceptive approach.
    Lemay A, Faure N.
    J Clin Endocrinol Metab; 1986 Dec; 63(6):1379-85. PubMed ID: 2946711
    [Abstract] [Full Text] [Related]

  • 3. Luteinizing hormone-releasing hormone agonist and uterine leiomyoma: a pilot study.
    Maheux R, Guilloteau C, Lemay A, Bastide A, Fazekas AT.
    Am J Obstet Gynecol; 1985 Aug 15; 152(8):1034-8. PubMed ID: 3927734
    [Abstract] [Full Text] [Related]

  • 4. Regression of uterine leiomyomata in response to the antiprogesterone RU 486.
    Murphy AA, Kettel LM, Morales AJ, Roberts VJ, Yen SS.
    J Clin Endocrinol Metab; 1993 Feb 15; 76(2):513-7. PubMed ID: 8432797
    [Abstract] [Full Text] [Related]

  • 5. Treatment of uterine leiomyomata with a luteinizing hormone-releasing hormone agonist: the possibility of nonsurgical management in selected perimenopausal women.
    Nakamura Y, Yoshimura Y, Yamada H, Ubukata Y, Ando M, Suzuki M.
    Fertil Steril; 1991 May 15; 55(5):900-5. PubMed ID: 1902420
    [Abstract] [Full Text] [Related]

  • 6. Suppression of follicular maturation by infusion of a luteinizing hormone-releasing hormone agonist starting during the late luteal phase in the stumptailed macaque monkey.
    Fraser HM, Sandow J.
    J Clin Endocrinol Metab; 1985 Mar 15; 60(3):579-84. PubMed ID: 3919049
    [Abstract] [Full Text] [Related]

  • 7. [Treatment of leiomyomas with luteinizing hormone-releasing hormone agonist].
    Nakamura Y, Yoshimura Y, Yamada H, Maruyama K, Nanno T, Ubukata Y, Ando M, Takahashi K, Suzuki M.
    Nihon Sanka Fujinka Gakkai Zasshi; 1990 Dec 15; 42(12):1620-6. PubMed ID: 2126024
    [Abstract] [Full Text] [Related]

  • 8. Long-term follow-up of patients with uterine fibroids after treatment with the LHRH agonist buserelin.
    Matta WH, Shaw RW, Nye M.
    Br J Obstet Gynaecol; 1989 Feb 15; 96(2):200-6. PubMed ID: 2495020
    [Abstract] [Full Text] [Related]

  • 9. Treatment of uterine fibroids with implants of gonadotropin-releasing hormone agonist: assessment by hysterography.
    Donnez J, Schrurs B, Gillerot S, Sandow J, Clerckx F.
    Fertil Steril; 1989 Jun 15; 51(6):947-50. PubMed ID: 2498131
    [Abstract] [Full Text] [Related]

  • 10. Uterine leiomyoma: treatment with LHRH agonist.
    Maheux R, Lemay A.
    Prog Clin Biol Res; 1986 Jun 15; 225():297-311. PubMed ID: 3097669
    [No Abstract] [Full Text] [Related]

  • 11. Luteinizing hormone-releasing hormone analog therapy of uterine fibroid: analysis of results obtained with buserelin administered intranasally and goserelin administered subcutaneously as a monthly depot.
    Costantini S, Anserini P, Valenzano M, Remorgida V, Venturini PL, De Cecco L.
    Eur J Obstet Gynecol Reprod Biol; 1990 Oct 15; 37(1):63-9. PubMed ID: 2142921
    [Abstract] [Full Text] [Related]

  • 12. Total and unbound cytosolic estrogen and progesterone receptors in myometrium and fibroid after gonadotropin-releasing hormone agonist treatment.
    Fernández-Montolí ME, Díez-Gibert O, Samaniego JM, Balagueró L, Navarro MA.
    Fertil Steril; 1995 Mar 15; 63(3):522-7. PubMed ID: 7851581
    [Abstract] [Full Text] [Related]

  • 13. Subcutaneous injection or infusion of gonadotropin releasing-hormone agonist buserelin in the treatment of enlarged uteri harboring leiomyomata.
    Franssen AM, Willemsen WN, Corbey RS, Doesburg WH, van 't Veen AJ, Rolland R.
    Eur J Obstet Gynecol Reprod Biol; 1991 Jul 25; 40(3):221-8. PubMed ID: 1908799
    [Abstract] [Full Text] [Related]

  • 14. Suppression of luteal function by a luteinizing hormone-releasing hormone antagonist during the early luteal phase in the stumptailed macaque monkey and the effects of subsequent administration of human chorionic gonadotropin.
    Fraser HM, Nestor JJ, Vickery BH.
    Endocrinology; 1987 Aug 25; 121(2):612-8. PubMed ID: 3109885
    [Abstract] [Full Text] [Related]

  • 15. Uterine leiomyoma and LHRH agonist treatment. A preliminary report.
    Rolland R, Franssen AM, Willemsen WN, Corbey RS.
    Prog Clin Biol Res; 1986 Aug 25; 225():313-20. PubMed ID: 3097670
    [No Abstract] [Full Text] [Related]

  • 16. [Preoperative reduction of uterine leiomyoma by the GnRH-analog goserelin (zoladex)].
    Hackenberg R, Gesenhues T, Deichert U, Duda V, Sturm G, Schulz KD.
    Geburtshilfe Frauenheilkd; 1990 Feb 25; 50(2):136-9. PubMed ID: 2138580
    [Abstract] [Full Text] [Related]

  • 17. Regression of leiomyomata uteri following hypoestrogenism induced by repetitive luteinizing hormone-releasing hormone agonist treatment: preliminary report.
    Maheux R, Guilloteau C, Lemay A, Bastide A, Fazekas AT.
    Fertil Steril; 1984 Oct 25; 42(4):644-6. PubMed ID: 6436065
    [No Abstract] [Full Text] [Related]

  • 18. The roles of estradiol and progesterone in decreasing luteinizing hormone pulse frequency in the luteal phase of the menstrual cycle.
    Nippoldt TB, Reame NE, Kelch RP, Marshall JC.
    J Clin Endocrinol Metab; 1989 Jul 25; 69(1):67-76. PubMed ID: 2499593
    [Abstract] [Full Text] [Related]

  • 19. Luteolytic activity of LHRH and [D-Ser(TBU)6, des-Gly-NH2(10)]LHRH ethylamide: a new and physiological approach to contraception in women.
    Lemay A, Labrie F, Raynaud JP.
    Int J Fertil; 1980 Jul 25; 25(3):203-12. PubMed ID: 6108931
    [Abstract] [Full Text] [Related]

  • 20. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
    Beckers NG, Macklon NS, Eijkemans MJ, Ludwig M, Felberbaum RE, Diedrich K, Bustion S, Loumaye E, Fauser BC.
    J Clin Endocrinol Metab; 2003 Sep 25; 88(9):4186-92. PubMed ID: 12970285
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.